Literature DB >> 25678560

Neuronal death induced by misfolded prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment.

Minghai Zhou1, Gregory Ottenberg1, Gian Franco Sferrazza1, Christopher Hubbs2, Mohammad Fallahi3, Gavin Rumbaugh2, Alicia F Brantley4, Corinne I Lasmézas5.   

Abstract

The mechanisms of neuronal death in protein misfolding neurodegenerative diseases such as Alzheimer's, Parkinson's and prion diseases are poorly understood. We used a highly toxic misfolded prion protein (TPrP) model to understand neurotoxicity induced by prion protein misfolding. We show that abnormal autophagy activation and neuronal demise is due to severe, neuron-specific, nicotinamide adenine dinucleotide (NAD(+)) depletion. Toxic prion protein-exposed neuronal cells exhibit dramatic reductions of intracellular NAD(+) followed by decreased ATP production, and are completely rescued by treatment with NAD(+) or its precursor nicotinamide because of restoration of physiological NAD(+) levels. Toxic prion protein-induced NAD(+) depletion results from PARP1-independent excessive protein ADP-ribosylations. In vivo, toxic prion protein-induced degeneration of hippocampal neurons is prevented dose-dependently by intracerebral injection of NAD(+). Intranasal NAD(+) treatment of prion-infected sick mice significantly improves activity and delays motor impairment. Our study reveals NAD(+) starvation as a novel mechanism of autophagy activation and neurodegeneration induced by a misfolded amyloidogenic protein. We propose the development of NAD(+) replenishment strategies for neuroprotection in prion diseases and possibly other protein misfolding neurodegenerative diseases.
© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  neurodegeneration; neuroprotection; nicotinamide dinucleotide; prion; protein misfolding

Mesh:

Substances:

Year:  2015        PMID: 25678560      PMCID: PMC4840455          DOI: 10.1093/brain/awv002

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  84 in total

1.  Neuronal apoptosis in fatal familial insomnia.

Authors:  A Dorandeu; L Wingertsmann; F Chrétien; M B Delisle; C Vital; P Parchi; P Montagna; E Lugaresi; J W Ironside; H Budka; P Gambetti; F Gray
Journal:  Brain Pathol       Date:  1998-07       Impact factor: 6.508

2.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

3.  Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia.

Authors:  Weihai Ying; Guangwei Wei; Dongmin Wang; Qing Wang; Xiannan Tang; Jian Shi; Peng Zhang; Huafei Lu
Journal:  Front Biosci       Date:  2007-01-01

4.  SynGAP regulates synaptic strength and mitogen-activated protein kinases in cultured neurons.

Authors:  Gavin Rumbaugh; J Paige Adams; Jee H Kim; Richard L Huganir
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

Review 5.  Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease.

Authors:  Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2012-11-14       Impact factor: 21.566

6.  Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study.

Authors:  V Demarin; Sarkanji S Podobnik; D Storga-Tomic; G Kay
Journal:  Drugs Exp Clin Res       Date:  2004

7.  Disease-associated prion protein oligomers inhibit the 26S proteasome.

Authors:  Mark Kristiansen; Pelagia Deriziotis; Derek E Dimcheff; Graham S Jackson; Huib Ovaa; Heike Naumann; Anthony R Clarke; Fijs W B van Leeuwen; Victoria Menéndez-Benito; Nico P Dantuma; John L Portis; John Collinge; Sarah J Tabrizi
Journal:  Mol Cell       Date:  2007-04-27       Impact factor: 17.970

Review 8.  Physiological relevance of the endogenous mono(ADP-ribosyl)ation of cellular proteins.

Authors:  Maria Di Girolamo; Nadia Dani; Annalisa Stilla; Daniela Corda
Journal:  FEBS J       Date:  2005-09       Impact factor: 5.542

9.  Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis.

Authors:  Kathryn Moynihan Ramsey; Jun Yoshino; Cynthia S Brace; Dana Abrassart; Yumiko Kobayashi; Biliana Marcheva; Hee-Kyung Hong; Jason L Chong; Ethan D Buhr; Choogon Lee; Joseph S Takahashi; Shin-Ichiro Imai; Joseph Bass
Journal:  Science       Date:  2009-03-19       Impact factor: 47.728

Review 10.  Macrodomain-containing proteins: regulating new intracellular functions of mono(ADP-ribosyl)ation.

Authors:  Karla L H Feijs; Alexandra H Forst; Patricia Verheugd; Bernhard Lüscher
Journal:  Nat Rev Mol Cell Biol       Date:  2013-06-05       Impact factor: 94.444

View more
  28 in total

Review 1.  Pyridine Dinucleotides from Molecules to Man.

Authors:  Joshua P Fessel; William M Oldham
Journal:  Antioxid Redox Signal       Date:  2017-07-25       Impact factor: 8.401

Review 2.  Mitophagy and Alzheimer's Disease: Cellular and Molecular Mechanisms.

Authors:  Jesse S Kerr; Bryan A Adriaanse; Nigel H Greig; Mark P Mattson; M Zameel Cader; Vilhelm A Bohr; Evandro F Fang
Journal:  Trends Neurosci       Date:  2017-02-09       Impact factor: 13.837

Review 3.  Interplay between NAD+ and acetyl‑CoA metabolism in ischemia-induced mitochondrial pathophysiology.

Authors:  Nina Klimova; Aaron Long; Susana Scafidi; Tibor Kristian
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-24       Impact factor: 5.187

4.  Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt-Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress.

Authors:  Waqas Tahir; Saima Zafar; Franc Llorens; Amandeep Singh Arora; Katrin Thüne; Matthias Schmitz; Nadine Gotzmann; Niels Kruse; Brit Mollenhauer; Juan Maria Torres; Olivier Andréoletti; Isidre Ferrer; Inga Zerr
Journal:  Mol Neurobiol       Date:  2016-12-14       Impact factor: 5.590

Review 5.  Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.

Authors:  Luis Rajman; Karolina Chwalek; David A Sinclair
Journal:  Cell Metab       Date:  2018-03-06       Impact factor: 27.287

Review 6.  Modulating NAD+ metabolism, from bench to bedside.

Authors:  Elena Katsyuba; Johan Auwerx
Journal:  EMBO J       Date:  2017-08-07       Impact factor: 11.598

7.  Prion Infectivity Plateaus and Conversion to Symptomatic Disease Originate from Falling Precursor Levels and Increased Levels of Oligomeric PrPSc Species.

Authors:  Charles E Mays; Jacques van der Merwe; Chae Kim; Tracy Haldiman; Debbie McKenzie; Jiri G Safar; David Westaway
Journal:  J Virol       Date:  2015-09-30       Impact factor: 5.103

8.  NAD+ Supplementation Attenuates Methylmercury Dopaminergic and Mitochondrial Toxicity in Caenorhabditis Elegans.

Authors:  Samuel W Caito; Michael Aschner
Journal:  Toxicol Sci       Date:  2016-02-10       Impact factor: 4.849

9.  Temporal Resolution of Misfolded Prion Protein Transport, Accumulation, Glial Activation, and Neuronal Death in the Retinas of Mice Inoculated with Scrapie.

Authors:  M Heather West Greenlee; Melissa Lind; Robyn Kokemuller; Najiba Mammadova; Naveen Kondru; Sireesha Manne; Jodi Smith; Anumantha Kanthasamy; Justin Greenlee
Journal:  Am J Pathol       Date:  2016-08-09       Impact factor: 4.307

10.  NAMPT-Mediated NAD(+) Biosynthesis Is Essential for Vision In Mice.

Authors:  Jonathan B Lin; Shunsuke Kubota; Norimitsu Ban; Mitsukuni Yoshida; Andrea Santeford; Abdoulaye Sene; Rei Nakamura; Nicole Zapata; Miyuki Kubota; Kazuo Tsubota; Jun Yoshino; Shin-Ichiro Imai; Rajendra S Apte
Journal:  Cell Rep       Date:  2016-09-27       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.